230 related articles for article (PubMed ID: 36301338)
21. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Chari A; Martinez-Lopez J; Mateos MV; Bladé J; Benboubker L; Oriol A; Arnulf B; Rodriguez-Otero P; Pineiro L; Jakubowiak A; de Boer C; Wang J; Clemens PL; Ukropec J; Schecter J; Lonial S; Moreau P
Blood; 2019 Aug; 134(5):421-431. PubMed ID: 31113777
[TBL] [Abstract][Full Text] [Related]
22. Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia.
Cook G; Corso A; Streetly M; Mendeleeva LP; Ptushkin VV; Chan E; Ukropec J; Iraqi W; Al-Akabawi A; Pei H; Gaudig M; Petrucci MT; Alegre A; Mateos MV
Oncol Ther; 2021 Jun; 9(1):139-151. PubMed ID: 33630275
[TBL] [Abstract][Full Text] [Related]
23. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study.
Lu J; Fu W; Li W; Hu J; An G; Wang Y; Fu C; Chen L; Jin J; Cen X; Ge Z; Cai Z; Niu T; Qi M; Sun S; Gai X; Liu W; Liu W; Yang X; Huang X
Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):e699-e709. PubMed ID: 34108127
[TBL] [Abstract][Full Text] [Related]
24. Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.
Jullien M; Trudel S; Tessoulin B; Mahé B; Dubruille V; Blin N; Gastinne T; Bonnet A; Lok A; Lebourgeois A; Peterlin P; Garnier A; Chevalier P; Guillaume T; Thomaré P; Le Gouill S; Moreau P; Touzeau C
Ann Hematol; 2019 Jun; 98(6):1435-1440. PubMed ID: 30874850
[TBL] [Abstract][Full Text] [Related]
25. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Palumbo A; Chanan-Khan A; Weisel K; Nooka AK; Masszi T; Beksac M; Spicka I; Hungria V; Munder M; Mateos MV; Mark TM; Qi M; Schecter J; Amin H; Qin X; Deraedt W; Ahmadi T; Spencer A; Sonneveld P;
N Engl J Med; 2016 Aug; 375(8):754-66. PubMed ID: 27557302
[TBL] [Abstract][Full Text] [Related]
26. Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison.
Usmani SZ; Diels J; Ito T; Mehra M; Khan I; Lam A
Am J Hematol; 2017 Aug; 92(8):E146-E152. PubMed ID: 28474745
[TBL] [Abstract][Full Text] [Related]
27. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ
Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484
[TBL] [Abstract][Full Text] [Related]
28. [The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma].
Liu J; He HY; Li L; Lu J; Qiang WT; Guo P; Hou N; Jiang H; Du J; Fu WJ
Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):27-32. PubMed ID: 33677865
[No Abstract] [Full Text] [Related]
29. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Afifi S; Michael A; Lesokhin A
Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.
Oostvogels R; Jak M; Raymakers R; Mous R; Minnema MC
Br J Haematol; 2018 Oct; 183(1):60-67. PubMed ID: 30080247
[TBL] [Abstract][Full Text] [Related]
32. Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.
Van Sanden S; Ito T; Diels J; Vogel M; Belch A; Oriol A
Oncologist; 2018 Mar; 23(3):279-287. PubMed ID: 29192016
[TBL] [Abstract][Full Text] [Related]
33. Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma.
Gasparetto C; Lentzsch S; Schiller G; Callander N; Tuchman S; Chen C; White D; Kotb R; Sutherland H; Sebag M; Baljevic M; Bensinger W; LeBlanc R; Venner C; Bahlis N; Rossi A; Biran N; Sheehan H; Saint-Martin JR; Van Domelen D; Kai K; Shah J; Shacham S; Kauffman M; Lipe B
EJHaem; 2021 Feb; 2(1):56-65. PubMed ID: 35846104
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.
Xu XS; Dimopoulos MA; Sonneveld P; Ho PJ; Belch A; Leiba M; Capra M; Gomez D; Medvedova E; Iida S; Min CK; Schecter J; Jansson R; Zhang L; Sun YN; Clemens PL
Adv Ther; 2018 Nov; 35(11):1859-1872. PubMed ID: 30374808
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma.
Iida S; Ichinohe T; Shinagawa A; Suzuki K; Takezako N; Aoki M
Int J Hematol; 2018 Apr; 107(4):460-467. PubMed ID: 29260507
[TBL] [Abstract][Full Text] [Related]
36. Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma.
Chehab S; Panjic EH; Gleason C; Lonial S; Nooka AK
Future Oncol; 2018 Dec; 14(30):3111-3121. PubMed ID: 30136602
[TBL] [Abstract][Full Text] [Related]
37. Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma.
Beksac M; Aydin Y; Goker H; Turgut M; Besisik SK; Cagirgan S; Tuglular T; Vural F; Yagci M; Alacacioglu I; Aytan P; Goksoy HS; Gulbas Z; Gunes AK; Gurkan E; Hacioglu SK; Karti SS; Kaynar L; Ozdogu H; Paydas S; Solmaz S; Sonmez M; Tekgunduz E; Yildirim R; Ilhan O
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e474-e484. PubMed ID: 32482539
[TBL] [Abstract][Full Text] [Related]
38. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
Chari A; Lonial S; Mark TM; Krishnan AY; Stockerl-Goldstein KE; Usmani SZ; Londhe A; Etheredge D; Fleming S; Liu B; Ukropec J; Lin TS; Jagannath S; Nooka AK
Cancer; 2018 Nov; 124(22):4342-4349. PubMed ID: 30395359
[TBL] [Abstract][Full Text] [Related]
39. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma.
Salomon-Perzyński A; Walter-Croneck A; Usnarska-Zubkiewicz L; Dytfeld D; Zielińska P; Wojciechowska M; Hołojda J; Robak P; Pasternak A; Knopińska-Posłuszny W; Hawrylecka D; Wójtowicz M; Szeremet A; Osowiecki M; Mordak-Domagała M; Zaucha JM; Giannopoulos K; Warzocha K; Jamroziak K
Adv Med Sci; 2019 Sep; 64(2):349-355. PubMed ID: 31125864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
